MedPath

Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease

Not Applicable
Recruiting
Conditions
Dry Eye Syndromes
Registration Number
NCT06089317
Lead Sponsor
Chinese University of Hong Kong
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

<br><br> 1. At least one eye of subjects meets DED diagnostic criteria as the Tear Film and<br> Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS II); and<br><br> 2. Ocular Surface Disease Index (OSDI)=13 and <33; and<br><br> 3. The age range between years 18-80, no sex limitation; and<br><br> 4. Symptoms of dry eye for at least 6 months; and<br><br> 5. Can complete the questionnaires independently and understand Chinese or English.<br><br>Exclusion criteria:<br><br> 1. Had or currently suffering from other concomitant ocular surface diseases, including<br> chronic conjunctivitis, ocular rosacea, cicatricial pemphigoid, graft-versus-host<br> disease, limbal stem cell deficiency, and severe ocular allergy;<br><br> 2. Received any refractive surgery and corneal surgery before, including corneal<br> transplant; or any eye surgery in the past 6 months;<br><br> 3. Receiving DED-related medications, including topical steroid eyedrops, topical<br> antibiotics, topical cyclosporin A, and topical diquafosol;<br><br> 4. Received intense pulsed laser (IPL) or vectored thermal pulsation (VTP) therapy in<br> the past 12 months;<br><br> 5. Received topical antiglaucomatous treatment in the past 12 months<br><br> 6. Plans to use contact lenses during treatment and follow-up periods or used contact<br> lenses 2 weeks before the baseline measurement and recruitment;<br><br> 7. Had or currently suffering from severe cardiopulmonary disease, liver and kidney<br> dysfunction, and severe blood system diseases;<br><br> 8. Suffering from glucose-6-phosphate dehydrogenase deficiency (G6PD);<br><br> 9. Had or currently suffering from specific respiratory diseases, e.g. emphysema,<br> bronchitis, asthma, chronic obstructive pulmonary disease, bronchial dilatation;<br><br> 10. Has adverse reaction history to herbs used in this study before;<br><br> 11. Whose TCM constitution is manifested as yang-deficiency or diagnosed by TCM<br> practitioners that their TCM syndrome is not suitable for the atomization treatment;<br><br> 12. Pregnancy, preparation for pregnancy, or lactation;

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in the Ocular Surface Disease Index (OSDI);Change in Non-invasive Tear Break-up Times (NIBUT)
Secondary Outcome Measures
NameTimeMethod
Change in Ocular Surface Disease Index (OSDI);Change in symptom Assessment iN Dry Eye (SANDE, modified);Change in 36-Item Short Form Health Survey (SF-36);Change in the Work Productivity and Activity Impairment Questionnaire: General Health V2.0 (WPAI:GH);Change in Non-Invasive Tear Break Up Times (NIBUT);Changes in Tear Meniscus Height (TMH);Changes in Bulbar Redness;Changes in Lipid Layer Thickness;Changes in Partial Blinking Rate;Changes in Meiboscore;Change in Tear Film Breakup Time (TBUT);Change in Corneal and Conjunctival Fluorescein Staining;Change in Expressibility of Meibomian Glands in the Meibomian Glands Yielding Liquid Secretion (MGYLS) (the inferior eyelid);Change in Quality of Expressed Meibum;Change in Lid Margin and Eyelash Abnormalities;Change in Tear Film Osmolarity (TFO);Changes in Schirmer I test;Changes in Matrix metallopeptidase 9 (MMP-9);Adverse events (AEs)
© Copyright 2025. All Rights Reserved by MedPath